Black Diamond director granted 7,707 shares

Black Diamond Therapeutics director Ali Behbahani received stock in lieu of director cash fees, increasing his reported direct and indirect equity exposure.

Rhea-AI Filing Summary

Black Diamond Therapeutics, Inc. (symbol: BDTX) is the issuer of record for a Form 4 filing submitted to the SEC. Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.

Black Diamond Therapeutics, Inc. (BDTX) director Ali Behbahani reported receiving 7,707 shares of common stock on September 18, 2026 as a grant under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in lieu of cash fees, valued using the $1.93 September 17, 2026 closing price.

Following this award, Behbahani holds 110,236 shares directly and has indirect exposure to 4,448,757 shares held by New Enterprise Associates 16, L.P., where he participates through related general partner entities and disclaims beneficial ownership of portions in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 7,707 shares

Grant/Award 2 txns

Insider Behbahani Ali

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	7,707	$1.93	$15K
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 110,236 shares (Direct); Common Stock — 4,448,757 shares (Indirect, See Note 3)

Footnotes (3)

1. F1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.
3. F3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

Key Figures

Shares granted: 7,707 shares Grant valuation price: $1.93 per share Direct holdings after transaction: 110,236 shares +2 more

5 metrics

Shares granted 7,707 shares Common stock grant to director on September 18, 2026

Grant valuation price $1.93 per share Closing market price on September 17, 2026 used for the award

Direct holdings after transaction 110,236 shares Ali Behbahani direct ownership after September 18, 2026 grant

Indirectly held shares 4,448,757 shares Shares held by New Enterprise Associates 16, L.P. reported as indirect, subject to disclaimed beneficial ownership

Transaction date September 18, 2026 Date of non-employee director stock grant

Key Terms

Sixth Amended and Restated Non-Employee Director Compensation Policy, beneficial ownership, pecuniary interest, Section 16 of the Securities Exchange Act of 1934

4 terms

Sixth Amended and Restated Non-Employee Director Compensation Policy regulatory

"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy"

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership within the meaning of Section 16"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership ... of such portion of the securities ... in which the Reporting Person has no pecuniary interest"

Section 16 of the Securities Exchange Act of 1934 regulatory

"beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did BDTX director Ali Behbahani report on this Form 4?

He reported a grant of 7,707 shares of Black Diamond Therapeutics common stock on September 18, 2026, received under the company’s Non-Employee Director Compensation Policy in lieu of cash compensation for his annual service as a non-employee director.

At what price was the BDTX director stock grant valued?

The 7,707-share grant to Ali Behbahani was valued at $1.93 per share, based on the closing market price of Black Diamond Therapeutics common stock on September 17, 2026, as stated in the filing footnotes.

How many BDTX shares does Ali Behbahani hold directly after the reported grant?

After the September 18, 2026 grant, Ali Behbahani holds 110,236 shares of Black Diamond Therapeutics common stock directly, according to the post-transaction holdings reported in the Form 4.

What indirect holdings in BDTX are associated with Ali Behbahani?

The Form 4 reports 4,448,757 Black Diamond Therapeutics shares held indirectly through New Enterprise Associates 16, L.P. Behbahani is a manager of related general partner entities and disclaims beneficial ownership of any portion in which he has no pecuniary interest.

Was the BDTX Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmatively marked, and there is no footnote stating that the September 18, 2026 stock grant occurred under a Rule 10b5-1 trading plan.

Why did Ali Behbahani receive BDTX shares instead of cash?

The footnotes state the shares were issued under Black Diamond Therapeutics’ Sixth Amended and Restated Non-Employee Director Compensation Policy, after he elected to receive common stock in lieu of cash compensation for his annual services as a non-employee director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 05:46 PM Accepted by SEC EDGAR 09/21/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL RD

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2026		A(1)		7,707	A	$1.93(2)	110,236	D
Common Stock								4,448,757	I	See Note 3(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.

3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

	/s/ Zachary Bambach, attorney-in-fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)